A pH-Responsive Drug-Delivery System Based on Apatinib-Loaded Metal-Organic Frameworks for Ferroptosis-Targeted Synergistic Anti-Tumor Therapy
Fengyi Yang,Qiaoyan Dong,Zhuo Chen,Benjian Gao,Dongning Zheng,Rui Wang,Shu Qin,Fangyi Peng,Ming Luo,Jin Yang,Mengmei Nie,Bo Li,Xiaoli Yang
DOI: https://doi.org/10.2147/ijn.s477248
IF: 7.033
2024-09-05
International Journal of Nanomedicine
Abstract:Fengyi Yang, 1, 2, &ast Qiaoyan Dong, 3, &ast Zhuo Chen, 1, 2, &ast Benjian Gao, 1, 2, &ast Dongning Zheng, 1, 2 Rui Wang, 1, 2 Shu Qin, 1, 2 Fangyi Peng, 1, 2 Ming Luo, 1, 2 Jin Yang, 1, 2 Mengmei Nie, 4 Bo Li, 1, 2 Xiaoli Yang 1, 2 1 Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China; 2 Academician (Expert) Workstation of Sichuan Province, Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China; 3 Luzhou Senior High School, Luzhou, 646000, People's Republic of China; 4 Department of Urological Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Bo Li; Xiaoli Yang, Email ; Purpose: The efficacy of systemic therapy for hepatocellular carcinoma (HCC) is limited mainly by the complex tumor defense mechanism and the severe toxic side-effects of drugs. The efficacy of apatinib (Apa), a key liver cancer treatment, is unsatisfactory due to inadequate targeting and is accompanied by notable side-effects. Leveraging nanomaterials to enhance its targeting represents a crucial strategy for improving the effectiveness of liver cancer therapy. Patients and Methods: A metal polyphenol network-coated apatinib-loaded metal-organic framework-based multifunctional drug-delivery system (MIL-100@Apa@MPN) was prepared by using metal-organic frameworks (MOFs) as carriers. The nanoparticles (NPs) were subsequently characterized using techniques such as X-ray diffraction (XRD), transmission electron microscopy (TEM), zeta potential measurements, and particle size analysis. In vitro experiments were conducted to observe the drug release kinetics and cytotoxic effects of MIL-100@Apa@MPN on HepG2 cells. The in vivo anti-tumor efficacy of MIL-100@Apa@MPN was evaluated using the H22 tumor-bearing mouse model. Results: The formulated MIL-100@Apa@MPN demonstrates remarkable thermal stability and possesses a uniform structure, with measured drug-loading (DL) and encapsulation efficiency (EE) rates of 28.33% and 85.01%, respectively. In vitro studies demonstrated that HepG2 cells efficiently uptake coumarin-6-loaded NPs, and a significant increase in cumulative drug release was observed under lower pH conditions (pH 5.0), leading to the release of approximately 73.72% of Apa. In HepG2 cells, MIL-100@Apa@MPN exhibited more significant antiproliferative activity compared to free Apa. In vivo, MIL-100@Apa@MPN significantly inhibited tumor growth, attenuated side-effects, and enhanced therapeutic effects in H22 tumor-bearing mice compared to other groups. Conclusion: We have successfully constructed a MOF delivery system with excellent safety, sustained-release capability, pH-targeting, and improved anti-tumor efficacy, highlighting its potential as a therapeutic approach for the treatment of HCC. Keywords: metal-organic frameworks nanoparticles, apatinib, drug-targeting delivery, ferroptosis therapy, hepatocellular carcinoma Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. 1 Currently, targeted therapy is the primary treatment modality for HCC, with apatinib (Apa) being the most representative drug. 2 Apa is a highly specific inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase complex, demonstrating a strong anti-angiogenic effect. 3–5 However, it lacks target specificity, leading to frequent severe adverse effects, such as hand-foot syndrome, hypertension, and proteinuria. When used as a monotherapy for targeting HCC, Apa showed a modest improvement in median overall survival (OS), with an increase of just 1.9 months. 6 Its objective remission rate (ORR) was only 15.73%. 7 Therefore, there is an urgent need to enhance the targeting capabilities of Apa. Metal-organic frameworks (MOFs) have allured considerable attraction in light of their porous structure, which renders them versatile for use in catalysis, drug encapsulation, and drug-delivery applications. 8–11 Iron-based MOF (MIL-100) is receiving extensive attention due to its high porosity and effective drug-loading, promising potential for applications in biomedicine -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology